Thallous chloride
As of the edition of 20 October 2026, Thallous chloride is a small molecule: marketed, first approved in 1982 (US); no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1982
- Kind
- Small molecule
- First approved
- 1 January 1982 (US)
- Approvals on record
- 5 in 1 region
- Holder of the most recent approval
- Lantheus Medical Imaging; 4 holders in all
- Registered trials
- 1, 0 stopped early
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 1 | 0 | 0 |
| All trials | 1 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| GE Healthcare | Later holder | 1996 to now |
| Bracco Diagnostics | Acquired holder | 2003 to now |
| Lantheus Medical Imaging | Acquired holder | 2008 to now |
| Curium | Acquired holder | 2019 to now |
| Byk-Mallinckrodt CIL | Later holder |